TYROSINE KINASE INHIBITOR (TKI) THERAPY IN COMPANION ANIMALS: YEAR ONE

摘要

Inhibitors of tyrosine kinases (TKIs) have become an integral part of human cancer therapy over the past 5-10 years. Drugs such as Gleevec, Sutent, Sorafenib, Tarceva, among others, are now routinely used to treat a variety of cancers including chronic myelogenous leukemia, gastrointestinal stromal tumor, renal cell carcinoma, lung cancer, among others. A number of inhibitors are now in clinical trials as well. Despite the widespread use of such inhibitors in the human arena, l'imited data exists onthe clinical efficacy of TKIs in veterinary medicine. In part, this is due to the fact that tumor types in which such inhibitors may work are only beginning to be defined. Additionally, many of the human TKIs are currently cost-prohibitive, preventing their widespread use. In June 2009, the first TKI for use in canine cancer patients, Palladia (toceranib phosphate) was approved by the FDA. The following review will summarize the recent clinical experience with Palladia in treating dogs with cancer.